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SUMMARY
Expression of the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase associated with cell
proliferation and survival, is overactive in many tumors of epithelial origin. Blockade of the kinase activity
of EGFR has been used for cancer therapy; however, by itself, it does not seem to reach maximum therapeu-
tic efficacy.We report here that in human cancer cells, the function of kinase-independent EGFR is to prevent
autophagic cell death by maintaining intracellular glucose level through interaction and stabilization of the
sodium/glucose cotransporter 1 (SGLT1).INTRODUCTION
As a member of the receptor tyrosine kinase family, the epider-
mal growth factor receptor (EGFR), upon ligand binding, dimer-
izes, autophosphorylates, and triggers cascades of downstream
signaling, such as activation of phosphatidylinositol-3-kinase/
Akt, mitogen-activated protein kinase (MAPK), Jak/Stat, and
protein kinase C and modulation of ion channels, by which cell
proliferation and survival are enhanced (Wells, 1999). Overex-
pression/activation of EGFR, which is often found in tumors of
epithelial origin, is associated with metastasis, poor prognosis,
and resistance to chemotherapy (Nicholson et al., 2001), which
makes it an ideal target for therapy.Multiple clinical trials of using
EGFR tyrosine kinase inhibitors in cancer therapy have been
conducted, but blockage of tyrosine kinase activity alone does
not seem to reach maximum therapeutic efficacy. The general
response rates are between 10%–20% across a variety of hu-
man malignancies (Fukuoka et al., 2002; Kris et al., 2002; Cohen
et al., 2003; Dancey and Freidlin, 2003).
The expression level of EGFR in cancer tissues is correlated
with prognosis, but not with responsiveness, to EGFR tyrosinekinase inhibitor treatment (Arteaga, 2002), suggesting that, inde-
pendent of its kinase activity, EGFR may contribute to the pro-
gression of cancer. The existence of kinase-independent prosur-
vival function of EGFR is supported by several studies. First of all,
loss of kinase activity of EGFR does not produce similar pheno-
types as to loss of EGFR protein in vivo. EGFR knockout animals
die soon after birth (Miettinen et al., 1995), but animals with se-
verely compromised kinase mutant EGFR are completely viable
and display only some epithelial defects (Luetteke et al., 1994).
Second, EGFR without kinase activity was shown to be able to
stimulate DNA synthesis (Coker et al., 1994) and enhance cell
survival (Ewald et al., 2003). Finally, inhibition of the kinase activ-
ity of EGFR by tyrosine kinase inhibitors often leads to decreased
cell proliferation but not cell death (Harari and Huang, 2004),
whereas knocking down the EGFR receptor protein results in
cell death (Nagy et al., 2003).
In this study, we investigated the mechanism of kinase-inde-
pendent prosurvival function of the EGFR and found that, inde-
pendent of its kinase activity, EGFR prevents cancer cells from
autophagic cell death by maintaining the basal intracellular glu-
cose level.SIGNIFICANCE
Overexpression/activation of EGFR, which is often found in tumors of epithelial origin, is associated with metastasis, poor
prognosis, and resistance to chemotherapy. Multiple clinical trials using EGFR tyrosine kinase inhibitors in cancer therapy
have been conducted; however, blockage of tyrosine kinase activity alone does not seem to reach maximum therapeutic
efficacy.We report here that EGFR, independent of its kinase activity, maintains the basal intracellular glucose level, thereby
preventing cells from undergoing autophagic death. This function of EGFR may endow tumor cells with an increased sur-
vival capacity even in the presence of chemotherapeutic agents and tyrosine kinase inhibitors. Thus, the inhibition of this
function and of the kinase activity of EGFR may both be necessary for eradication of epithelial neoplasms.Cancer Cell 13, 385–393, May 2008 ª2008 Elsevier Inc. 385
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Loss of Expression of EGFR, but Not Its Kinase Activity,
Resulted in Autophagic Cell Death
PC-3MM2cellswerecultured inminimumessentialmedium (MEM)
containing physiological glucose content of 5.5 mM (Baltzan et al.,
1962). As shown in Figure 1A, EGFR tyrosine kinase inhibitor,
AEE788 (Traxler et al., 2004) (5.0 mM), did not decrease the expres-
sion of EGFRbut did completely inhibit its phosphorylation. In con-
trast, the transfection of the cells with EGFR siRNA decreased the
expression of the EGFR (Figure 1B). As shown in Figure 1C, unlike
control cells, treatment of PC-3MM2cellswith AEE788 (5.0 mM) for
3 days led to inhibition of cell proliferation, but not to cell death.
However, incubation of PC-3MM2 cells transfected with EGFR
siRNA for 3 days in MEM resulted in cell death, as indicated by
the presence of sub-G1 cells. The use of the commercial EGFR ki-
nase inhibitor, AG1478 (data not shown), and different siRNA
against EGFR produced similar results (Figure S1 available online).
To characterize the cell death due to loss of the EGFR protein,
we measured EGFR downstream signalings Akt and MAPK and
apoptotic-associated caspases 9 and 3 by western blotting.
Contrary to our expectation, the knocking down of EGFR by
siRNA led to upregulation of phosphorylatedAkt (pAkt) andphos-
phorylated MAPK (pMAPK) without changes in Akt and MAPK
levels (Figure 2A). Only procaspases 9 and 3 were detected,
Figure 1. Blocking the Kinase Activity of EGFRDoesNot Lead to Cell
Death but Knocking Down EGFR with siRNA Does
(A) PC3MM2 cells grown in MEM with 5.5 mM glucose were treated with
AEE788 (5.0 mM, with AEE788 readded every 24 hr) for 72 hr. Western blot
analysis revealed that pEGFR was completely blocked by AEE788 compared
with the control. b-actin served as a loading control (tEGFR, total EGFR).
(B) Seventy-two hours later after cells were cultured in MEM with 5.5 mM glu-
cose, tEGFR and pEGFR levels were both reduced by siRNA treatment com-
pared with the control that was transfected with siRNA vector-expressing
scrambled sequences. b-actin served as a loading control.
(C) Compared with the control cells (there was no difference between non-
transfected control cells and control siRNA vector transfected cells), AEE788
only caused a decrease in the proportion of cells in S phase (p < 0.01, arrow-
head) with no detectable sub-G1 cells (dead cells). However, the EGFR siRNA-
treated cells showed a significant (p < 0.01) proportion of sub-G1 cells (arrow).386 Cancer Cell 13, 385–393, May 2008 ª2008 Elsevier Inc.but not their cleaved forms, indicating that the cell death caused
by knocking down EGFR was not due to typical apoptosis.
To furtherelucidate themechanismsof thiscell death,weexam-
ined the cells with transmission electronmicroscopy. As shown in
Figure 2B, the EGFR siRNA-transfected cells contained multiple
autophagosomes: that is, lysosome-infused cytoplasmic organ-
elles in which the contents are degraded for energy production
(Kroemer and Jaattela, 2005). It is worth noting here that, as a sur-
vival mechanism triggered by an intracellular energy crisis, au-
tophagy provides cells with an energy backup mechanism, ulti-
mately leading to death if external energetic substrates remain
deprived (Lum et al., 2005). Aggregates of exogenous microtu-
bule-associated protein 1 light chain 3 (LC3) (Tanida et al., 2004)
were found in the cytoplasm of EGFR siRNA-transfected cells,
but not in the control cells (Figure 2C), providing additional evi-
dence that the cell death was due to autophagy. Treatment of
EGFR siRNA-transfected cells with the autophagy inhibitor 3-
methyladenine (Petiot et al., 2000) resulted in cell deathwith char-
acteristics of necrosis—translocation of HMGB1 (high mobility
group box 1) (Ito et al., 2007) from the nucleus to the cytoplasm
and cell lysis in situ (Figure S2). The autophagic phenotype in
PC-3MM2 cells treated with EGFR siRNA was also seen in other
cell types, for example, MDA-MB231 human breast cancer cells
and KM12C human colon cancer cells (Figures S3A and S3B).
Figure 2. Cell Death Induced by Knocking Down EGFRwith siRNA Is
Characterized as Autophagic Cell Death
(A) Western blot analysis of the activity of Akt, MAPK, and caspases 9 and 3 in
EGFR siRNA-treated cells. Both Akt and MAPK pathways were more active in
siRNA-treated cells than in control cells, as indicated by the upregulation of
phosphorylated Akt (pAkt) and MAPK (pMAPK); the total Akt (tAkt) and
MAPK (tMAPK) were not changed. No cleaved form of caspase 9 or 3 was de-
tected in the siRNA-treated cells; only their proforms (procaspase 9 and 3)
were present, indicating that the cell death caused by knocking down EGFR
was not a typical apoptosis. b-actin served as a loading control.
(B) Transmission electron microscopy of control and EGFR siRNA-treated
cells. Knocking down EGFR resulted in the appearance of autophagosomes
(arrows) in the cytoplasm, which were absent from the control cells. (N, nu-
cleus; bar, 200 nm). (C) LC3 staining (arrow, red color) in control and EGFR
siRNA-transfected cells. Note that in the cytoplasm of control cells LC3 is dif-
fused, whereas LC3 is in aggregates in the EGFR-siRNA treated cells (arrows,
red color; bar, 2 mm).
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for Autophagic Cell Death Induced by EGFR
siRNA Treatment
Because glucose is themajor energy substrate for all cells and tu-
mor tissues accumulate and consumemore glucose than do nor-
mal tissues (Gatenby andGillies, 2004), we nextmeasured the in-
tracellular glucose level in cells treated with AEE788 and cells
transfectedwith EGFRsiRNA. Thedata shown in Figure 3A reveal
that 3 days of treatment with AEE788 did not alter the intracellular
glucose level. In sharp contrast, in cells treatedwith EGFRsiRNA,
3 days of culture inMEMcontaining 5.5mMglucose led to a 50%
decrease in the glucose level (Figure 3B). Similar data were found
in EGFR siRNA-treated human breast cancer MDA-MB231 and
human colon cancer KM12C cells (Figure S3C). Notably, the
cell death phenotype caused by the knocking down of EGFR
could be rescued by increasing the glucose content in the MEM
to the same level as in Dulbecco’s modified Eagle’s medium
with a high (25 mM) glucose level (Figure 3C). As shown in Fig-
ure 3D, incubating EGFR siRNA cells inMEMcontaining high glu-
cose levels also reversed the autophagic phenotype as indicated
by thedisappearanceof autophagosomes. Thecell deathcaused
by decreased EGFR expression was thus due to autophagy trig-
gered by a decreased intracellular glucose level. High glucose
MEM treatment also increased the intracellular glucose level (Fig-
ure 3E) and decreased pAKT and pMAPK (Figure 3F) of siRNA-
treated cells, suggesting the increased phosphorylation of AKT
and MAPK in response to EGFR knocking down (Figure 2A)
may be a stress response to lower intracellular glucose level.
Consequential Loss of SGLT1 following EGFR Knocking
Down Leads to a Decrease in Intracellular Glucose Level
Glucose is transported into cells by two families of transporter—
a facilitative-type glucose transporter family (GLUT) and an
active-type glucose transporter family (sodium/glucose cotrans-
porter [SGLT]) that in human cells consists of two major mem-
bers (SGLT1 and SGLT2). In response to stress or stimuli, such
as insulin and hormones, GLUTs translocate from the intracellu-
lar compartment to the cell membrane, thus transporting glu-
cose along a glucose gradient (inward or outward) (Wood and
Tryhurn, 2003). GLUT1 is the most wildly distributed, serving
many cell types for glucose uptake (Zierler, 1999). In contrast,
SGLT transports glucose into cells regardless of glucose con-
centration in the medium and cells depend on SGLT to accumu-
late andmaintain higher intracellular glucose levels (Wright et al.,
1994). SGLT1 is themajor active glucose transporter in the body,
and SGLT1 (but not SGLT2 measured by RT-PCR; data not
shown) was expressed in PC-3MM2 cells.
To investigate which glucose transporter systems may con-
tribute to the cell death phenotype caused by the EGFR knock-
down, wemeasured the expression of GLUT1 and SGLT1. In the
EGFR siRNA-treated cells, the expression of SGLT1 was re-
duced to undetectable levels while the expression of GLUT1
was not suppressed by the treatment (Figure 4A). In addition,
knocking down SGLT1 by SGLT1 siRNA was sufficient to pro-
duce autophagic cell death in low glucose (5.5 mM) MEM (Fig-
ures 4B–4D), which can be rescued by high glucose (25 mM)
MEM (Figure 4C). Together, these results raise an interesting
possibility that EGFR knocking down-induced SGLT1 downre-
gulation contributed to the autophagic cell death.EGFR Interacts with SGLT1 Independent of the Kinase
Activity of EGFR
Next, we measured the protein and mRNA expression of SGLT1
in PC-3MM2 cells over time after knocking down EGFR by using
siRNA. As shown in Figure 5A, the protein level of EGFR de-
creased at 24 hr and even more at 48 hr after transient
Figure 3. Knocking Down EGFR Leads to Decreases in Intracellular
GlucoseLevel, and Increasing theGlucoseContent in theCultureMe-
dium Rescues the Cell from Death Caused by Knocking Down EGFR
(A) Measurement of intracellular glucose content. AEE788 (5.0 mM) treatment
for 72 hr did not alter the intracellular glucose content. (Error bars indicate
mean ± SD.)
(B) The glucose content of EGFR siRNA-treated cells was significantly de-
creased (p < 0.001) compared with that of control cells after a 72 hr culture
in MEM with 5.5 mM glucose. (Triplicate samples were used in each group.
The asterisk indicates a significant difference with p < 0.001. Error bars indi-
cate mean ± SD.)
(C) Culturing EGFR siRNA-transfected cells in high glucose (25 mM) MEM
(hgMEM) significantly reduced (p < 0.01) the cell death proportion, as indicated
by the decrease in sub-G1 cells (arrow). (Triplicate samples were used in this
experiment.)
(D)The hgMEM-treated cells also lead to disappearance of autophagosomes
on transmission electron microscopy (bar, 2 mm).
(E) The intracellular glucose level was also restored by hgMEM treatment.
(Error bars indicate mean ± SD.)
(F) Western blotting shows that hgMEM treatment was also able to inhibit the
enhanced activation of AKT and MAPK induced by knocking down EGFR.Cancer Cell 13, 385–393, May 2008 ª2008 Elsevier Inc. 387
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the SGLT1 protein and intracellular glucose level. The mRNA
level of EGFR decreased in response to EGFR siRNA treatment,
whereas the mRNA level of SGLT1 did not (both measured by
reverse transcriptase-polymerase chain reaction [RT-PCR])
(Figure 5B). These results suggest that the downregulation of
SGLT1 in cells treated with EGFR siRNA occurred at the protein
level. To test whether the decrease of SGLT1 was due to its deg-
radation, we added the proteasome inhibitor MG132 to the me-
dium with the EGFR siRNA-treated cells. As shown in Figure 5C,
the addition of MG132 rescued the level of SGLT1, indicating
that the decrease in SGLT1 in response to knocking down
EGFR is due to degradation.
Because both EGFR and SGLT1 are membrane proteins, one
possibility is that they physically interact with each other. To test
this, we performed an immunoprecipitation assay. Using the
anti-EGFR specific antibody C225 (Goldstein et al., 1995), we
were able to coprecipitate SGLT1 with EGFR, independent of
EGFR phosphorylation (Figure 5D). To further test the kinase in-
dependence of the EGFR-SGLT1 interaction, we coexpressed
wild-type EGFR (WT-EGFR) or kinase domain-mutated EGFR
(kmtEGFR) (Chan and Gill, 1996) with SGLT1 in human MCF-7
Figure 4. Knocking Down EGFR Leads to Downregulation of SGLT1,
and Knocking Down SGLT1 Results in a Similar Cell Death Pheno-
type as Knocking Down EGFR
(A) No changes onGLUT1 expression were detected by knocking down EGFR,
but SGLT1 was downregulated to an undetectable level. b-actin served as
a loading control.
(B) Cells treated with SGLT siRNA led to downregulation of SGLT1 after 4 days
of culture in MEM.
(C) This treatment also led to a significant proportion of cell deaths (p < 0.01) as
evidenced by the presence of sub-G1 cells (arrow), and hgMEM was able to
prevent cells from death. (The flow cytometry data of control vector-trans-
fected cells were similar to those of the control cells used in the EGFR siRNA
experiment in Figure 2.)
(D) As with the EGFR siRNA-treated cells, cells that underwent SGLT1 siRNA
treatment also showed a large amount of autophagosomes (arrows) on trans-
mission electron microscopy (bar, 2 mm).388 Cancer Cell 13, 385–393, May 2008 ª2008 Elsevier Inc.cells, which express very low level of EGFR protein (Davidson
et al., 1987). As shown in Figure 5E, immunoprecipitation of
EGFR with the C225 antibody coprecipitated SGLT1 with either
WT-EGFR or kmtEGFR. These results support the conclusion
Figure 5. EGFR Interacts with and Stabilizes SGLT1 Independent of
EGFR Kinase Activity
(A) Western blot revealed a time-dependent downregulation of SGLT1 by
knocking down EGFR with siRNA (con, control). At each time point, levels of
glucose were measured. *p < 0.05.
(B) RT-PCR analysis of EGFR mRNA and SGLT1 mRNA in response to EGFR
siRNA treatment (con, control). The EGFR mRNA became downregulated at
48 hr after EGFR siRNA treatment, whereas the SGLT1 mRNA level remained
unchanged.
(C) Proteasome inhibitor MG132 blocked the downregulation of SGLT1 by
EGFR siRNA; siRNA and MG132 treatments were for 24 hr. Actin was used
as an internal control.
(D) EGFR physically interacted with SGLT1, independent of EGFR kinase ac-
tivity, as revealed by coimmunoprecipitation with the anti-EGFR antibody
C225. PC3MM2 cells were cultured in serum-free medium for 12 hr before be-
ing treatedwith 40 ng/ml EGF or with EGF and AEE788 (EGF/AEE). The blotting
of immunoprecipitates was against SGLT1, total EGFR, pEGFR, and GLUT1.
Normal mouse IgG was used as a negative control).
(E) kmtEGFR also interacted with SGLT1 as did WT-EGFR in MCF-7 cells co-
transfected with WT-EGFR/SGLT1 or kmtEGFR/SGLT1.
(F) HA-SGLT1 was coimmunoprecipitated with myc-EGFR and myc-ECD, but
not myc-ICD.
(G) Western blotting detection of HA-SGLT1 coexpressed with myc-tagged
full-length (FL), the extracellular domain (ECD containing the transmembrane
domain), and intracellular domain (ICD) of EGFR in HEK293 cells. Note that
HA-SGLT1 was only efficiently coexpressed with full-length EGFR, to much
less extent with ECD, but not with ICD of EGFR (IP, immunoprecipitation; IB,
immunoblotting; n.s., nonspecific band).
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EGFR kinase activity.
To illustrate which domains of EGFR, intracellular or extracel-
lular-transmembrane domain, interacts with SGLT1, we used
two truncated forms of EGFR (Hsu and Hung, 2007): one has
only the intracellular domain (ICD) and the other has both the
transmembrane and extracellular domains (ECD). These two
truncated forms of EGFR contain myc tags at their C termini.
We also created C-terminal HA-tagged SGLT1. We coex-
pressed HA-tagged SGLT1 with myc-tagged full-length ICD
or ECD of EGFR individually in HEK293 cells. As shown in
Figure 5F, the full-length EGFR was coprecipitated with
SGLT1. To a lesser extent, SGLT1 was also coprecipitated
with ECD, but not with ICD. Consistently, HA-SGLT1 was effi-
ciently coexpressed with full-length EGFR, to a much less
extent with ECD, but not expressed with ICD (Figure 5G).
Together, the results suggest that ECD of EGFR is required
for interaction with SGLT1 and the full-length EGFR is required
to efficiently stabilize SGLT1.
Because both WT-EGFR and kmtEGFR interacted with
SGLT1, we reasoned that both should be able to rescue the au-
Figure 6. Rescue Cells Treated with EGFR siRNA from Death by
Re-Expression of WT-EGFR or kmtEGFR
(A) PC-3MM2 cells were treated with siRNA targeting the 50UTR region of
EGFR mRNA, which downregulated the EGFR level after a 4-day siRNA treat-
ment. Both WT-EGFR and kmtEGFR were re-expressed in the siRNA-treated
cells and were able to upregulate SGLT1 expression. The absence of kinase
activity of kmtEGFR was shown by western blotting with an anti-pEGFR anti-
body. b-actin served as a loading control.
(B) The re-expression of WT-EGFR and kmtEGFR also rescued the EGFR
siRNA-treated cells from death. The sub-G1 proportion is indicated by the
arrows. (Duplicate samples were used in each group of samples.) tophagic death phenotype in cells transfected with EGFR siRNA
by stabilizing SGLT1. We therefore designed siRNA to target the
50UTR of the EGFRmRNA. The use of expression vectors lacking
the 50UTR sequence of EGFR allowed the reexpression of
WT-EGFR or kmtEGFR in the PC-3MM2 cells. As shown in
Figure 6A, the 50UTR siRNA dramatically downregulated the
EGFR level in treated versus control vector-transfected PC-
3MM2 cells. Moreover, the transient expression of either WT-
EGFR or kmtEGFR preserved SGLT1 (Figure 6A) and rescued
the cells from death (Figure 6B).
Survival Advantage of EGFR/SGLT1 Expressing Cells
in Medium with Low Level of Glucose
Considering the status of EGFR overexpression in malignant tu-
mors and the stability dependency of SGLT1 on EGFR expres-
sion, we argue that the more EGFR/SGLT1 tumor cells harbor,
the less they depend on the level of extracellular glucose for sur-
vival. To test it, we compared the sensitivity of three cell lines to
glucose starvation: A431, PC3-MM2, and MCF-7 representing
high, medium, and low/no EGFR expression, respectively
(Figure 7A). Both EGFR-expressing cells A431 and PC3-MM2
expressed SGLT1, but MCF-7 did not. Each type of cell was cul-
tured in three kinds of medium containing high (25 mM),
Figure 7. Survival Advantage of EGFR/SGLT1-Expressing Cells in
a Low Level of Glucose Medium
(A) Western Blotting analysis demonstrated that SGLT1 was expressed in
EGFR-positive cells, A431 and PC3-MM2, but not in MCF-7.
(B) When A431, PC3-MM2, andMCF-7 cells were cultured inmedia containing
different levels of glucose, 25 mM, 5 mM, and 3 mM, for 3 days, only MCF-7
cells showed significant degree of cell death. (Error bars indicate mean ± SD.)
(C and D) Either EGFR or SGLT1 was transiently expressed in MCF-7 cells cul-
tured in 25 mM containing MEM. Forty-eight hours later after the transfection,
medium was changed to MEM containing 3 mM glucose. After a 2 day incuba-
tion in low glucose MEM, cells were either fixed for cell death analysis by flow
cytometry (C) or harvested for western blotting analysis of EGFR and SGLT1
(D). (Triplicate samples were used in each group of samples. Asterisks repre-
sent statistical significance as compared with cells grown in high glucose [25
mM] medium, p < 0.05. Error bars indicate mean ± SD.)Cancer Cell 13, 385–393, May 2008 ª2008 Elsevier Inc. 389
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days, and cell death wasmeasured by flow cytometry. As shown
in Figure 7B, the EGFR-expressing cells A431 and PC3-MM2 are
resistant to glucose starvation-induced cell death, while EGFR
low cells, MCF-7, could not survive even in 5 mM glucose-con-
taining medium (Figure 7B). In addition, overexpression of either
EGFR or SGLT1 resulted in enhanced survival of MCF-7 cells in
low glucoseMEM (Figure 7C). Due to very low expression level of
SGLT1 in MCF-7 cells (undetectable by WB in Figure 7A but de-
tectable mRNA by RT-PCR; data not shown), the SGLT1 expres-
sion in the EGFR-transfected MCF-7 cells is not as high as
SGLT1-transfected MCF-7 cells (Figure 7D, lane 2 versus lane
3). It is worthwhile to mention that transfection of EGFR in
MCF-7 cells showed better prosurvival effect than transfection
of SGLT1 alone (Figure 7C versus Figure 7D). Thus, in addition
to the EGFR-stabilized SGLT1, other mechanisms induced by
traditional EGFR-mediated pathway may also contribute to the
prosurvival phenotype shown in Figure 7C. Together, the results
support survival advantage of EGFR/SGLT1 expression for cells
cultured in the low glucose medium.
DISCUSSION
Activation of EGFR has been reported to transiently increase glu-
cose transport (Inman and Colowick, 1985). We reproduced this
transient increase in glucose uptake following the activation of
EGFR in PC-3MM2 cells by exposure to EGF in serum-free me-
dium. This activation was abrogated by the presence of the
EGFR tyrosine kinase inhibitor AEE788 (Traxler et al., 2004)
(Figure S4). Inhibition of EGFR phosphorylation, however, only
blocked the peak glucose uptake and did not decrease the level
of intracellular glucose to below that found in cells whose EGFR
was not activated (Figure S4). These data suggest that peak glu-
cose intake into cells requires EGFR kinase activity, but mainte-
nance of a basal level of intracellular glucose does not. Indeed,
expression of nonphosphorylated EGFR is often observed in
normal human tissues (Hudelist et al., 2006) as well as in multiple
tumor samples (Piazzi et al., 2006), where the role of EGFR may
likely be maintaining basal glucose uptake required for survival.
Although kinase-independent functions of EGFR have been
reported previously (Coker et al., 1994; Ewald et al., 2003), ef-
forts to understand the role of EGFR have been largely directed
to its kinase-related activity. The yet unimpressive clinical out-
comes of EGFR tyrosine kinase inhibitors for treatment of multi-
ple types of cancer suggest that kinase independent functions of
EGFR may be a significant contributor for cancer progression.
The prosurvival and proproliferation roles of EGFR might be
mediated by at least two separated pathways. Activation of the
EGFR by its ligands results in increased cell proliferation, which
is often supported by data of deceleration of cell proliferation by
inhibitions of tyrosine kinase activity of EGFR (Mendelsohn,
2001; Rodeck et al., 1997; Peng et al., 1996). However, very
rarely (Wu et al., 1995), inhibition of the tyrosine kinase activity
of EGFR leads to cell death. The lack of cytotoxicity of inhibitors
of EGFR tyrosine kinase may partially explain the clinical out-
come of using tyrosine kinase inhibitors in cancer treatment
(Dancey and Freidlin, 2003).
Our present study shows that EGFR is a stabilizer of an active
glucose transporter, SGLT1, empowering cancer cells with the390 Cancer Cell 13, 385–393, May 2008 ª2008 Elsevier Inc.ability to uptake the basic energy substrate, glucose, regardless
the level of extracellular glucose, for their survival. Maintaining
a sufficient level of intracellular ATP is required to prevent cells
from dying. There is at least one commonality among different
kinds of cell deaths, apoptosis, necrosis, and autophagic cell
deaths, which is an energy crisis triggered at different levels
along their death pathways. During apoptosis, ATP level sharply
decreases when mitochondria lose their transmembrane poten-
tial. In hypoxia-induced necrosis, the most common cause of
necrosis in vivo, depletion of ATP precedes mitochondrial
permeability alteration. Autophagy, a process of self-degrada-
tion to complement environmental energy/nutrient paucity, is
also characterized with ATP insufficiency occurring prior to cell
death (Lemasters et al., 2002; Skulachev, 2006). The presence
of SGLT1 allows cancer cells to uptake enough glucose for
ATP generation via glycolysis (Nishimura et al., 1998). In general,
when mitochondria are dysfunctional, high levels of glucose or
ATP can prevent/delay cell deaths, such as apoptosis (Malhotra
and Brosius, 1999; Palaga et al., 2004; Honda et al., 2003) and
necrosis (Kinzer and Lehmann, 1991).
In normal tissues where active glucose uptake is critical for
the body, such as the epithelium of intestine, tubules of the kid-
ney (Lee et al., 1994), and vascular endothelium of the brain (El-
feber et al., 2004), EGFR and SGLT1 are coexpressed. In fact,
activation of EGFR in the epithelium of intestine leads to active
transport of glucose (Hardin et al., 1996). Using EGFR/SGLT1
double-negative (at mRNA level) HEK293 cells, we found that ex-
ogenous SGLT1 could only be expressed when EGFR was co-
transfected (Figure S5), supporting the notion that EGFR may
stabilize SGLT1. The higher content of glucose in tumor cells,
as compared to normal cells (Gatenby and Gillies, 2004) requires
the active glucose transport system SGLT. Considering the fact
that EGFR is overexpressed in tumors of epithelial origin and our
current finding that EGFR stabilizes SGLT1, we postulate that
SGLT1 might also be overexpressed in EGFR-positive tumors.
Indeed, it was reported that SGLT1 is overexpressed in preneo-
plastic and neoplastic lesions of the head and neck (Helmke
et al., 2004) (i.e., in cells that express high levels of EGFR [Ford
and Grandis, 2003]). Whether SGLT1 is also overexpressed in
other types of epithelial neoplasms remains to be determined.
In summary, we report that EGFR, independent of its kinase
activity, maintains the basal intracellular glucose level, thereby
preventing cells from undergoing autophagic death. This func-
tion of EGFR may endow tumor cells with an increased survival
capacity even in the presence of chemotherapeutic agents and
tyrosine kinase inhibitors (Ikari et al., 2005). Thus, the inhibition
of this function and of the kinase activity of EGFR may both be
necessary for eradication of epithelial neoplasms.
EXPERIMENTAL PROCEDURES
Cell Line and Major Reagents
The human metastatic prostate cancer cell line PC-3MM2 was selected from
the parental PC3 line in our laboratory (Pattaway et al., 1996). The breast can-
cer cell lines MCF-7 (originally from the American Type Culture Collection,
Manassas, VA) andMDA-MB-231, the skin cancer cell line A431, and the colon
cancer cell line KM12C were obtained from The University of Texas M.D. An-
derson Cancer Center (Houston, TX). The GeneJuice transfection reagent was
from Novagen (San Diego, CA). The U6 promoter-driven siRNA vector with
green fluorescent protein (GFP) expression (pRNAT-U6.1/Neo for EGFR,
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(Piscataway, NJ). The target sequences for EGFR siRNA were CGCAAAGT
GTGTAACGGAATA within exon 13 of the EGFR gene and CTGACTCCGTC
CAGTATTGAT within the 50UTR region of EGFR mRNA. Validated commercial
control (cat. no. 4635) and two different EGFR siRNAs (Cat. 51334) (used in
experiments shown in Figure S1 were from Ambion [Austin, TX]). The target
sequence for SGLT1 siRNA was TCTTCCGCATCCAGGTCAAT. The negative
control siRNA sequence was GAACAATGTTGACCAGGTGA. The SGLT1-ex-
pressing vector SGLT1- pCMV6-XL4 was from OriGene Technologies (Rock-
ville, MD). LC3 cDNAwas a gift of Dr. Seiji Kondo (M.D. Anderson Cancer Cen-
ter). Antibodies against total EGFR (cat. no. 2232), pEGFR (cat. no. 2434L),
total Akt (cat. no. 9277), phosphorylated AKT (cat. no. 9271L), total MAPK
(cat. no. 9102), and phosphorylated MAPK (9101L) were from Cell Signaling
Technology (Danvers, MA). Antibodies against SGLT1 (cat. no. ab14685)
andGLUT1 (cat. no. Ab652) were fromAbcam, Inc. (Cambridge, MA). Antibody
against HMGB1 (cat. no. H9537) was from Sigma-Aldrich (St. Louis, MO). The
monoclonal antibody against C225 was a gift from Dr. Liana Adam (M.D. An-
derson Cancer Center). Mouse anti-myc-tag antibody (cat. no. 05-724) and
anti-HA-tag antibody (cat. no. 05-904) were fromMillipore (Billerica, MA). Rab-
bit anti-caspase 9 (cat. no. sc-7885); goat anti-caspase 3 (cat. no. sc-1225);
rabbit anti-actin (cat. no. sc-7210); and secondary antibodies against rabbit,
mouse, or goat labeled with horseradish peroxidase and protein A/G conju-
gated agarose beads (cat. no. sc-2003) were from Santa Cruz Biotechnology
(Santa Cruz, CA). EGFR tyrosine kinase inhibitor AEE788 was from Novartis
Pharma (Basel, Switzerland). Commercial EGFR kinase inhibitor AG1478
was from EMD Bioscience (San Diego, CA). Autophagy inhibitor 3-methylade-
nine was from Sigma-Aldrich (St. Louis, MO). Proteasome inhibitor MG132
was from Sigma-Aldrich.
Construction of N-Terminal HA-Tagged SGLT1
To construct the HA-tagged SGLT1, the human SGLT1 full-length cDNA was
amplified by PCR using SGLT1-pCMV6-XL4 as a template with the following
primers: 50-CTAGTTAAGCTTGGATGGACAGTAGCACCTGGAGC-30 and 50-A
GCGGCCGCCAGCAGGCAAAATATGCA-TGGC-30. The DNA fragments were
digested with HindIII and NotI and cloned into the corresponding sites of
the modified pcDNA6A vector (Invitrogen, CA), in which myc epitope has
been replaced with hemaglutinin (HA). The cDNA inserts were confirmed by
DNA sequencing.
Treatment with Tyrosine Kinase Inhibitor AEE788 and AG1478
AEE788 and AG1478 were dissolved in dimethyl sulfoxide (vehicle) and then
added to the medium in the indicated concentrations, respectively. Control
PC-3MM2 cells were treated with medium containing the same volume of
the vehicle. For glucose uptake experiments, triplicate cultures of PC-3MM2
cells grown in serum-free medium for 12 hr were treated with the vehicle,
EGF (40 ng/ml), or EGF plus AEE788 (0.1 mM), and cells were harvested at 5,
10, 20, 30, 50, and 60min after treatment and then assayed for glucose uptake
(data are shown in Figure S4).
Cell Transfections
To knock down EGFR or SGLT1 expression by using siRNA, PC-3MM2 cells
were cultured inMEM supplemented with 10% fetal bovine serum, sodium py-
ruvate, nonessential amino acids, L-glutamine, and a two-fold vitamin solution
in 5%CO2%–95% air at 37C. Vectors expressing siRNA (targeting exon 13 of
the EGFR gene) for EGFR, SGLT1, and their corresponding controls were
transfected into the PC-3MM2, MDA-MB-436, and KM12C cells using Gene-
Juice. With GFP used as a tracer, the cells were sorted 24 hr later with a cell-
sorting machine (BD FACS Vantage SE system; BD Biosciences, Palo Alto,
CA) that used green fluorescence as a selector. The effects of siRNA on the ex-
pression of the target gene were evaluated by western blotting 24 hr after the
sorted cells were reseeded and cultured. Treatment of PC-3MM2 cells with
commercial validated control and EGFR siRNAs was done by transient trans-
fection of cells with 100 nM of each siRNA. EGFR expression and analysis of
cell death were determined 96 hr after transfection. For each set of experi-
ments, 1.0 3 106 cells with GFP expression were used in each triplicate sam-
ple. For 3-methyladenine treatment, a final concentration of 1 mM 3- methyla-
denine was added to the medium of EGFR siRNA transfected cells 6 hr after
sorting. The immunocytochemical staining of HMGB1 was conducted 24 hrlater after the 3-methyladenine treatment. The morphological changes of
3-methyladenine-treated cells were monitored by a converted light micro-
scope.
To re-express the WT-EGFR or kmtEGFR, we first knocked down EGFR in
PC-3MM2 cells with siRNA (50UTR-siRNA), targeting the 50UTR region of
EGFR mRNA, which allowed us to use an EGFR-expressing vector that does
not contain the 50UTR region of EGFR. Triplicate cultures of PC-3MM2 cells
were then transfected with 50UTR-siRNA, and 24 hr later, the cells were sorted
by using a GFP as a selection marker. The sorted cells were then transfected
with either an empty vector (pcDNA3.1[]) or a vector containing WT-EGFR or
kmtEGFR. For LC3 overexpression in control and EGFR siRNA-transfected
cells, twelve hours after the siRNA treatment, we transiently transfected 1 mg
cDNA of LC3 into 1.0 3 106 cells. For immunocytochemical staining of LC3,
the cells were fixed with 70% ethanol after a 72 hr culture in MEM.
To test the interaction betweenWT-EGFR or kmtEGFR and SGLT1, we used
MCF-7 low EGFR-expressing cells. The cells (duplicate) were cultured for 24 hr
in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum prior
to cotransfection with empty vectors (pcDNA3.1 and pCMV6-SPORT6),
WT-EGFR/SGLT1, kmtEGFR/SGLT1, or only SGLT1. The cells were harvested
24 hr after transfection and subjected to immunoprecipitation with a C225
antibody. The precipitates were analyzed for EGFR, phosphorylated EGFR,
and SGLT1 by western blotting.
To test which domain of EGFR interact with SGLT1, 1 mg cDNA of myc-
tagged EGFR with either intracellular domain truncation or extracellular
domain truncation was transiently transfected into PC3MM2 cells culture in
6-well plate. Control cells were transfected an equal amount of vector DNA.
Forty-eight hr after transfection, cells were harvested for immunoprecipitation
with a mouse anti-myc antibody. A positive control was also included, which is
protein extracts of PC3MM2 cells immunoprecipitated with a mouse anti-
EGFR C225. The precipitates were analyzed for the presence of SGLT1 by
western blotting.
Measurement of Intracellular Glucose and ATP
Prior to harvesting, adherent cultures of control and EGFR siRNA-treated cells
in MEM containing 1 mg/ml glucose were washed twice with cold phosphate-
buffered saline (PBS) and then lysedwith ion-free H2O for 5min on ice. The glu-
cose content was measured with D-glucose measurement kit (GAHK-20,
Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s protocol. Intra-
cellular ATP level was measured using Bioluminescent Somatic Cell Assay
Kit (cat. no. FLASC, Sigma-Aldrich) according to the protocol provided by
the manufacturer. The level of ATP is reflected by the amount of generated
bioluminescence measured by a Luminescence Meter (Monolight 2010, San
Diego, CA).
Measurement of Cell Survival in Medium with Low
and High Glucose Medium
PC-3MM2, A431, and MCF-7 cells were cultured in MEM containing low glu-
cose (3 or 5 mM) or in MEM supplemented with an additional 3.5 mg/ml D-
glucose (high glucose MEM, containing a total of 25 mM glucose). Triplicate of
sorted siRNA-expressing cells cultured for 3 or 4 days (indicated in the figure
legends) in either MEM or high-glucose MEM were used to test survival in re-
sponse to changes in the environment. The population of sub-G1 cells (as an
indicator of cell death) was determined by flow cytometry. Briefly, trypsinized
cells were washed once with MEM containing serum and then washed three
times with cold PBS and fixed for 3 hr in cold ethanol (70% v/v). The cells
were then centrifuged at 2,000 3 g, resuspended in PBS containing 0.05%
propidium iodide and 10 mg/ml RNase A, and incubated for 30 min at 37C
before analysis with a fluorescence-activated cell sorter (FACS Elite; BD
Biosciences).
Western Blot Analysis
For western blot analysis, PC-3MM2 cells were incubated for 10 min at 0C in
a lysis buffer (50 mM HEPES, pH 7.4; 150 mM NaCl; 0.1% Triton X-100; 1.5
mM MgCl2; 1 mM EDTA; and 1 mM phenylmethlysulfonyl fluoride). Equal
amounts of proteins pooled from triplicate samples separated by 7% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) were trans-
blotted to nitrocellulose, blocked with 5% nonfat dry milk for 2 hr at room tem-
perature, and then incubated overnight with primary antibodies (all at a 1:2000Cancer Cell 13, 385–393, May 2008 ª2008 Elsevier Inc. 391
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membranes were washed for 10 min with a washing buffer (PBS solution con-
taining 0.1% NP40) before incubation with corresponding secondary anti-
bodies conjugated with horseradish peroxidase (all at a 1:3000 dilution). After
a 30minwashing, immunoreactive signals were visualized by enhanced chem-
iluminescence.
Immunoprecipitation
The physical interaction between EGFR and SLGT1 was detected by immuno-
precipitation. Briefly, cells were lysed by scraping them with a rubber police-
man into a lysis buffer (50 mM HEPES, pH 7.4; 150 mM NaCl; 0.1% Triton
X-100; 1.5 mM MgCl2; 1 mM EDTA; and 1 mM phenylmethlysulfonyl fluoride)
and then incubated for 10 min at 0C, followed by a 5 s sonication (Sonic Dis-
membrator; Fisher Scientific, Pittsburgh, PA). The lysates were then cleared by
centrifugation for 10 min at 14,000 3 g. Protein extracts containing 500 mg
protein were subsequently incubated for 12 hr at 4C with the anti-EGFR
monoclonal antibody C225 (10 ng), mouse anti-myc (10 ng), mouse anti-HA
(10 ng), or with nonspecific normal mouse immunoglobulin G (IgG) (10 ng)
(as a negative control). At that time, 50 ml protein A/G beadswere added to pre-
cipitate the EGFR complex. The precipitates were washed twice with a lysis
buffer and then denatured by heating in sample buffer. Immunoprecipitates
were resolved on a 7.5%SDS-PAGE gel followed by transfer to a nitrocellulose
membrane. The presence of EGFR, phosphorylated EGFR, SGLT1, myc-
EGFR, myc-ECD,myc-ICD, and HA-SG LT1was detected bywestern blotting.
RT-PCR to Analyze Changes of EGFR and SGLT1mRNA in Response
to Treatment with EGFR
PC-3MM2 cells treated with EGFR siRNA were cultured for 24 and 48 hr in the
presence or absence of the proteasome inhibitor MG132 (5 mM). At each time,
total RNA prepared using Trizol reagent (Ambion, Inc., Austin, TX) was col-
lected from triplicate samples. RT-PCR was performed with a one-step
RT-PCR kit (BD Biosciences) to detect themRNA levels of SGLT1, SGLT2, and
EGFR. The mRNA level of b-actin was used as an internal control. The se-
quences of primers for EGFR were 50-TTTCGATACCCAGGACCAAGCCA
CAGCAGG-30 and 50- AATATTCTTGCTGGATGCGTTTCTGTA-30, for SGLT1
were 50- TGGCAGGCCGAAGTA-TGGTGT-30 and 50-ATGAATATGGCCCCC
GAGAAGA-30, for SGLT2 were 50ACACGGACACGGTACAGACCTT-30 and
50-GAACAGCACAATGGCGAAGTAGA-3, and for b-actin were 50-ATCTGGC
ACCACACCTTCTACAATG-30 and 50-CGTCATACTC-CTGCTTGCTG-30. The
RT-PCR reaction programwas set to 50C for 1 hr and 94C for 5min, followed
by 30 cycles of 94C for 40 s, 56C for 40 s, and 72C for 50 s with an extension
at 72C for 10 min. The PCR products were analyzed with a 1% agarose gel
stained with ethidium bromide and visualized under ultraviolet light.
Transmission Electron Microscopy
Transmission electron microscopy was conducted by Kenneth Dunner, Jr., in
the High Resolution Electron Microscopy Facility at M.D. Anderson (www.
mdanderson.org/HREMF).
Statistical Analysis
The Student’s t test was used to assess the difference of glucose levels of cells
treated with AEE788 and EGFR siRNA and the difference of cell counts at each
‘‘phase’’ of cell cycle of treated and control cells. p < 0.01 was defined as the
statistical significance.
SUPPLEMENTAL DATA
The Supplemental Data include five supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/5/
385/DC1/.
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